Hormonal
GLP-1 receptor agonists (specifically semaglutide and liraglutide) are the most effective pharmacological interventions for weight loss, producing significantly greater total body weight loss than other FDA-approved anti-obesity medications.
If you have obesity, lifestyle changes alone are rarely enough for long-term success due to your body's biological resistance. Semaglutide (Ozempic/Wegovy) is currently the most effective drug available, helping patients lose an average of 12.4% of their body weight when combined with diet and exercise. It requires a weekly injection. If cost is a barrier, discuss insurance coverage (sometimes available for diabetes) or cheaper alternatives like phentermine-topiramate with your doctor. The goal is to find a regimen you can tolerate and afford for the long term.
Semaglutide is the most effective agent. Phentermine-topiramate, naltrexone-bupropion, liraglutide, lisdexamfetamine, and pramlintide are also associated with a high percentage of total body weight loss. Orlistat, topiramate alone, metformin, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a more modest weight loss.
Why this rating
Based on multiple randomized controlled trials (RCTs) cited in Table 3 (e.g., STEP 1, STEP 2).
Source
Antiobesity drug therapy: An individualized and comprehensive approach
Yael Mauer et al. · Cleveland Clinic Journal of Medicine · 2021
DOI 10.3949/ccjm.88a.20080
More from this paper
- Phentermine-topiramate extended-release is a highly effective alternative for weight loss, particularly for patients who cannot use GLP-1 agonists, achieving high percentages of total body weight loss.Strong
- Bariatric weight loss surgery is significantly more effective than pharmacotherapy and lifestyle modifications for long-term weight loss and improvement of comorbid conditions in eligible patients, yet remains severely underutilized.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →